Mutants of the eukaryote Saccharomyces cerevisioe, previously selected for resistance to diphtheria toxin, were investigated for their suitability as hosts for the expression of tox-related proteins. The structural gene for the toxin, encoding the fragment A catalytic domain, was modified for efficient intracellular expression in eukaryotes and placed downstream of the yeast GAL) promoter element in a plasmid.
contrast, sensitive, wild-type cells harboring this plasmid grew normally under repressing conditions but were killed when the GALI promoter was induced. Additional constructions were also prepared that included sequences encoding either the lymphocyte growth factor interleukin 2 or a-melanocytestimulating hormone along with the lipid-associating domains of fragment B and the leader peptide ofthe Kluyveromyces lactis killer toxin. Resistant mutant strains transformed with these plasmids efficiently expressed and secreted the expected chimeric toxins.
The lethal action of diphtheria toxin on susceptible cells is mediated by the inhibition of protein synthesis through the ADP-ribosylation of elongation factor 2 (EF-2) (1). A single molecule of the toxin in the cytoplasm is sufficient to kill mammalian cells (2) . This toxin-catalyzed activity is specific for EF-2 and occurs at a unique posttranslational histidine derivative, diphthamide (3, 4) , found in a conserved amino acid sequence (5) in the EF-2 of all eukaryotes and archaeobacteria examined thus far (6) . Rare eukaryotic mutant cell lines defective in this posttranslational modification possess EF-2 that cannot serve as a substrate for diphtheria toxin, and they are thus resistant to its cytotoxic effects (7) .
Because of the profound cytotoxicity, well-characterized mode of action, and defined mechanism of cellular transport of diphtheria toxin, its fragments have been employed in the construction of hybrid toxins. These conjugate toxins have been assembled by the chemical modification and disulfide linkage of the toxin catalytic fragment with cell-surfacedirected agents such as monoclonal antibodies and peptide hormones. Although target-specific toxicity has been demonstrated (8) (9) (10) (11) (12) , the stoichiometry and sites of linkage of such conjugates are heterogeneous, creating complications for their application and confounding the interpretation of experimental results.
To obviate these problems, fusion genes ofdiphtheria toxin and a-melanocyte-stimulating hormone (a-MSH) or diphtheria toxin and interleukin 2 (IL-2) have recently been constructed (13) (14) (15) . In these chimeric proteins, the native diphtheria toxin receptor-binding domain is genetically replaced by the sequence for the specific peptide hormone or growth factor. The expression of these fusion genes in the prokaryote Escherichia coli produces chimeric toxins that exhibit selective toxicity in vitro and in vivo for eukaryotic cells bearing the surface receptors for the ligand component of the hybrid (14, 40) . Earlier studies, however, have shown that proteolysis of the fusion protein limits the use of E. coli as an expression vehicle (16) .
The eukaryote Saccharomyces cerevisiae has proven to be of particular utility for the cloning and expression of heterologous proteins because it is readily amenable to biochemical manipulation and genetic engineering to avoid proteolysis and to enhance yield. We recently reported a selection procedure for mutants of S. cerevisiae defective in the synthesis of diphthamide and consequently resistant to the in vitro action of diphtheria toxin (17) . In this work, we have used these resistant yeast mutants as hosts for the genetic expression of diphtheria toxin fragment A (DTA) and diphtheria toxin fusion proteins. The mutants are capable ofviably expressing functional DTA in the cytosol. In addition, the further incorporation of the leader sequence of the Kluyveromyces lactis killer toxin results in the secretion of the chimeric IL-2-toxin and a-MSH-toxin into the culture medium. These observations establish a precedent for the stable genetic expression of toxins and related fusion proteins in resistant mutants of eukaryotic cells.
METHODS
Strains, Media, and Growth Conditions. The bacterial and yeast strains used in this study are listed in Table 1 . The derivation of diphtheria toxin-resistant mutants (dph) from S. cerevisiae strain 3482-16-1 has been described (17) .
To transfer the toxin resistance mutations to strains capable of utilizing galactose, the 3482-16-1 mutants were mated with strain SSL204 (MATa his3-200 trpi Ieu2 ade2-101 ura3-52 GAL) (19) or strain LG1-1D (MATa ura3-52 his4-519 ade GAL) (20) . The resulting diploids were sporulated, tetrads were dissected, and the spore phenotypes were characterized. Haploid strains were identified that were diphtheria toxin-resistant as well as capable of utilizing galactose. Strain JP1-A, thus derived from a dph5 mutant, was employed to study the intracellular expression of DTA, whereas strains FG100-2A and FG100-11B, derived from a dph3 mutant, were used for the secretion studies.
Yeast YEP medium has been described (21) . For secretion studies, YEP medium was buffered with 0.1 M morpholinoethanesulfonic acid to pH 6.3. Yeast succinate-buffered medium (SB medium) consisted of minimal medium (21) Abbreviations: EF-2, elongation factor 2; IL-2, interleukin 2; a-MSH, a-melanocyte-stimulating hormone; DTA, diphtheria toxin fragment A. §Present address: Seragen, Inc., Hopkinton, MA 01748.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. Table 2 . Plasmid DNAs were prepared by the alkaline lysis method and purified on cesium chloride/ ethidium bromide gradients (24) . DNA was digested with restriction endonucleases as recommended by the manufacturer (New England Biolabs). Oligonucleotides were synthesized on an Applied Biosystems 380A DNA synthesizer and purified by electrophoresis on 10%o polyacrylamide/8 M urea gels. Bands were visualized after ethidium bromide staining and electroeluted into dialysis tubing. After desalting, the oligonucleotides were resuspended in TE buffer (10 mM Tris-HCl/1 mM Na2EDTA, pH 8.0) and equimolar concentrations of complementary strands were hybridized in the presence of 100 mM NaCl. In addition, a 5'-phosphorylated Cla I oligonucleotide linker (Pharmacia) was employed to provide a eukaryotic translation start codon. The addition of linkers to plasmids, agarose gel purification of restriction fragments, and cloning into plasmid vectors were conducted by standard methods (24) . Yeast strains were transformed with plasmid DNA as described by Beggs (25) or Ito et al. (26) .
Identification of Recombinant Toxin. Yeast strain JP1-A transformed with pGDTA7 was grown with agitation in 10 ml of SB selective medium with 2% galactose at 30°C to an OD6. = 1.0. Spheroplasts were prepared as described (17) and then lysed in 10 mM Tris HCl, pH 7.4/10 mM EGTA/10 mM EDTA/2 mM phenylmethylsulfonyl fluoride/10 ,g of pepstatin A per ml. After incubation at -20°C, =40 ,g of extract protein (27) was applied to a 0.1% NaDodSO4/8-18% polyacrylamide gradient gel and electrophoresed as described by Laemmli (28) . Proteins were transferred to nitrocellulose (29) and immunoblot analysis (30) was performed with polyvalent rabbit anti-diphtheria toxin serum, and peroxidase-conjugated goat anti-rabbit heavy and light chain specific IgG (Calbiochem). 3,4-Diaminobenzoic acid was used as a substrate with the addition of hydrogen peroxide. ADP-Ribosylation of EF-2 by Recombinant Diphtheria Toxin. Diphtheria toxin was obtained from Connaught Laboratory (Willowdale, Ontario, Canada). Yeast EF-2 was purified as described (3) . The activity of the expressed toxin in mutant yeast strains was determined by measuring the toxin catalyzed ADP-ribosylation of purified EF-2. JP1-A transformed with pGDTA7 was grown in galactose SB selective medium to an OD6. = 1.0, and cell extracts were prepared as described (17) . Total cellular protein (10-50 ,ug) was incubated with 10 1Lg of EF-2 in a reaction mixture containing 20 mM Tris-HCl (pH 7.5), 50 mM dithiothreitol, 1 mM EDTA, and 0.5 1LM [adenylate-32P]NAD' (-200,000 cpm) and analyzed for ADP-ribose incorporation (17) .
Identification of Secreted Toxins. Transformed yeast strains FG100-2A and FG100-11B were grown at 30'C to late logarithmic phase in buffered YEP medium containing either 2% glucose or 2% galactose. Cells were removed by centrifugation and, after passing the supernatant fluid through a 0.2-gkm filter, secreted tox gene products were precipitated with 10% trichloroacetic acid. Precipitates were collected by centrifugation at 4°C. Samples were neutralized with 0.1 M NaOH and were either resuspended in NaDodSO4 gel application buffer for immunoblot analysis or trypsin treated in TE buffer for ADP-ribosylation measurements.
RESULTS
Construction of a DTA Yeast Expression Plasmid. Plasmid pDT201 contains the 831-base-pair Sau3AI-2 fragment of corynebacteriophage j3ct"x5 in pUC8 and includes the prokaryotic diphtheria tox promoter, signal sequence, and fragment A (22) . Initiation of structural gene translation in Corynebacterium diphtheriae occurs at a GUG valine codon preceding a 24-amino acid signal sequence. An initial objective of this study was to determine if the yeast mutants resistant to the action of diphtheria toxin on EF-2 would be capable of expressing recombinant fragment A. To place the fragment A gene under the control of a eukaryotic promoter, we deleted most of the tox signal sequence and introduced an AUG codon to provide the appropriate in-frame initiation of translation. A synthetic phosphorylated Cla I linker containing an in-frame ATG sequence was cloned into the unique Apa I site of pDT201 after overhanging 3' nucleotides were removed by T4 DNA polymerase. The resulting construction contained the 6 carboxyl-terminal amino acids of the signal sequence with the fragment A gene intact. Cla I linkers were also cloned into the unique EcoRI site of pDT201 at the 5' end of fragment A encoding sequences (Fig. 1A) . This Cla I-fragment A cassette was subsequently ligated into pBM272 (M. Johnston, Washington University), to which a Cla I site had been introduced into the BamHI site downstream of the yeast GAL] promoter (Fig. 1B) Subsequently, cellular extracts of mutant strains were analyzed for the presence of functional and immunoreactive toxin product. The extracts were analyzed by gel electrophoresis and immunoblot, using polyclonal anti-diphtheria toxin serum. As shown in Fig. 2 Immunoblot analysis of culture supernatant fluids is presented in Fig. 4 . Galactose induction of the GAL-CYCI promoter resulted in the appearance of an immunoblotpositive protein in the culture medium of YEpsecI5O8-transformed cells (Fig. 4A, lane 2; Fig. 4B, lane 2) . As previously demonstrated with IL-2-toxin expressed in recombinant E. coli (pABI508) (15), IL-2-toxin expressed and secreted by FG100-11B (YEpsecI508) retains immunologic determinants of its diphtheria toxin-related and IL-2 components. Moreover, the appearance of an immunoreactive band of Mr 24,000 (Fig. 4A, lane 2) suggests that IL-2- toxin is partially cleaved and fragment A may be released following reduction under denaturing conditions. IL-2-toxin expressed and secreted into the culture supernatant fluid of yeast dph mutants has an apparent M, of 68,000 and was Detailed studies of the properties of chimeric toxins expressed in E. coli have been impeded by low levels of synthesis, insolubility, and proteolytic degradation (16) . Only by employing protease-deficient strains and a strong inducible promoter, conducting growth at low temperatures, and directing the expression of the chimeric toxin to the cytoplasm has it been possible to achieve efficient expression and recovery of intact proteins in E. coli (32) .
In S. cerevisiae, Baldari and co-workers (23) constructed an expression vector employing the putative leader sequence of the K. lactis killer toxin gene to effectively direct the secretion of human interleukin 1(3. Employing the same vector to target the a-MSH-toxin and IL-2-toxin fusion proteins, we also have observed efficient expression and secretion into the medium. In contrast to our studies in E. coli, the recombinant proteins produced in yeast dph mutants were soluble, active, and not subject to marked proteolysis. The yield of secreted recombinant IL-2-toxin far exceeds that of a previously reported S. cerevisiae level of 10 ,ug/liter of mouse IL-2 alone using the yeast a-factor promoter and leader sequence (33) .
Whereas a-MSH-toxin and IL-2-toxin are secreted in good yield, as measured by ADP-ribosyltransferase activity, only limited expression was observed by immunoblot. This is likely due to glycosylation of the secreted product. (38, 39) . Further, they also provide a powerful model useful to examine the elusive biology of the dph mutations and determine the role of diphthamide in protein synthesis. Finally, the general approach we have employed provides a unique opportunity to examine the biological properties of, and generate mutants to, other ADP-ribosyltransferases with distinct targets (e.g., guanine nucleotide-binding proteins) in a versatile eukaryote.
